Clinical trial NCT06606652: Caffeine, Resistance Exercise and EMG
Official title: Effect of Acute Caffeine Intake on Muscle Electrical Activity and Muscular Strength, Power, and Endurance Performance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Caffeine
Lead sponsor: University of Alcala
Sponsor class: OTHER
First posted: 2024-09-23
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: Introduction: Several studies have evaluated and confirmed the ergogenic effects of acute caffeine intake on sports performance. However, some studies suggest that this effect predominantly occurs in large muscle groups, potentially due to increased skeletal muscle electrical activity.

Objectives: This study aims to evaluate the acute effects of caffeine intake on strength, power, muscle endurance, and muscle electrical activity in young adults. It will also analyze the influence of circadian rhythms (morning vs. afternoon) on exercise performance (bench press vs. squat).

Methods: Twelve healthy, physically active participants will be recruited for the study. Using a triple-blind, crossover, randomized, and controlled design, participants will ingest either caffeine (3 mg/kg body mass) or a placebo (maltodextrin, 3 mg/kg) 60 minutes before the trial. Muscular strength, power, and endurance performance will then be assessed through 1RM tests, and at 25%, 50%, 75%, and 90% of 1RM, along with muscle endurance tests at 65% of 1RM, for both squat and bench press exercises. EMG will be used to measure skeletal muscle electrical activity during the tests. The experimental sessions will be conducted in the morning (8:00 am to 10:00 am) and the afternoon (4:30 pm to 6:30 pm).


Eligibility criteria: Inclusion Criteria:

* Age between 18 and 35 years.
* Body Mass Index (BMI) \&lt; 25 kg/m².
* Resistance-trained individuals (more than 2 years of structured training).
* Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from exercising.
* Participants must be able to perform the tests described in the following section.

Exclusion Criteria:

* History of neuromuscular diseases, heart disease, or conditions that may affect liver or muscle metabolism.
* Use of drugs, stimulants, or sports supplements that could interfere with the dietary supplement used in the study.
* Sedentary habits (less than 150 minutes/week of moderate exercise).
* Having undergone prolonged periods of physical inactivity in the 6 months prior to the study.
* Engaging in strenuous exercise within 48 hours prior to the tests.
* Failure to replicate the same food intake on both experimental days.
* Consumption of caffeine or any other stimulant after 6 pm on the day before the tests, to avoid headaches, discomfort, or lethargy in regular caffeine consumers.

Primary outcomes:
measure: Mean velocity at different %1RM
timeFrame: Through study completion, an average of 4 weeks
measure: Peak velocity at different %1RM
timeFrame: Through study completion, an average of 4 weeks
measure: Mean power output at different %1RM
timeFrame: Through study completion, an average of 4 weeks
measure: Peak power output and time to reach peak power output at different %1RM
timeFrame: Through study completion, an average of 4 weeks
measure: Number of repetitions performed in 1 set at 65%1RM until task failure
timeFrame: Through study completion, an average of 4 weeks
measure: Bar velocity deplacement performed in 1 set at 65%1RM until task failure
timeFrame: Through study completion, an average of 4 weeks
measure: Power output generated in 1 set at 65%1RM until task failure
timeFrame: Through study completion, an average of 4 weeks
measure: Muscle electrical activity (EMG).
timeFrame: Through study completion, an average of 4 weeks
Secondary outcomes:
measure: Mood state (tension, depression, anger, vigor, fatigue and confusion)
timeFrame: Through study completion, an average of 4 weeks
measure: Adverse effects
timeFrame: Through study completion, an average of 4 weeks
Other outcomes:
Locations:
city: Alcalá de Henares
country: Spain
facility: Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá
state: Madrid
Study officials:
References: